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Medical tourism (MT), the practice of  traveling  to another country to access medical care that   is 
paid for out of pocket, has received considerable attention in the Canadian news media. Stories 
depict Canadians traveling abroad for various  elective or necessary medical procedures, such as hip 
and knee replacements, bariatric surgery, and dental treatments.1,2 Commonly cited  safety  concerns  
of  MT  focus on the quality of care abroad and differences in safety standards or protocols in different 
health care systems.3 Medical tourists might be unable to bring their records home, disrupting 
continuity of care and challenging physicians’ abilities to provide appropriate follow-up care.4 Media 
and industry  information  sources,  which are commonly accessed by medical tourists, might 
inadequately inform Canadians about MT safety concerns.5,6 As a result, there is concern among 
Canadian  physicians and health and safety professionals that prospective medical tourists might not be 
well placed to make informed decisions about their care.7 As gatekeepers in the health care system and 
the first source of interaction between the health care system and patients, family physicians are well 
positioned to inform Canadians about these safety risks.8 
Safety concerns with MT are particularly relevant for patients traveling for 
unproven interventions—that is, interventions that have not been tested using recognized methods and 
proven to be safe and effective. While it is not currently possible to know how many Canadians are 
traveling abroad or what procedures they are undergoing, anecdotal evidence suggests 
Canadian medical tourists are traveling abroad for unproven interventions including chronic 
cerebrospinal venous insufficiency treatment of multiple sclerosis, stem cell interventions for many 
ailments, and untested bariatric surgical procedures.9,10 Patients engaging in MT for unproven 
interventions might be exposed to additional safety risks owing to the unproven nature of the 
intervention, face high financial burdens for potentially ineffective interventions, and be disqualified 
from enrolment in  legitimate  (and  free)  clinical  trials.11  When patients are diagnosed with a 
progressive or chronic disease, their hope for improved quality of life has the possibility of being 
exploited by providers of unproven interventions to promote uptake, heightening concerns about 
inadequately informed decision making from medical tourists engaging in this type of 
intervention.12  This  is not to say that all promoters of unproven interventions are charlatans 
preying on the weak, but the risk is real and substantial. 
There are numerous challenges that family physicians face in supporting more informed decision  
making by Canadians who are considering traveling abroad  for unproven interventions while 
also performing their legal and ethical duties to their patients. Physicians are constrained by 
trying to maintain a positive physician- patient relationship that honours patient autonomy 
and respects patients’ hope for treatment from unproven interventions while protecting patient 
safety. In this commentary we outline family physicians’ ethical and legal duties to these patients and 
discuss how the existing consensus on these duties does not adequately guide physicians’ actions. 
Duties to patients 
In its code of ethics, the Canadian Medical Association lists 54  physician  responsibilities  to  patients.13
Many of these responsibilities are particularly relevant in situations in which patients seek advice on 
accessing unproven interventions abroad. 
• “Take all reasonable steps to prevent harm to patients” (responsibility no. 14).
• “Recognize your limitations and, when indicated, recommend or seek additional opinions and
services” (responsibility no. 15). 
• “Provide your patients with the information they need to make informed decisions about their
medical care, and answer their questions to the best of your ability” (responsibility no. 21). 
• “Recommend only those diagnostic and therapeutic services that you consider to be
beneficial to your patient or to others” (responsibility no. 23).13
Together, these responsibilities focus on the role of the family physician in providing information and 
guidance to patients. 
Patients seeking unproven interventions via MT can access ethical guidance specific to these 
procedures. The International Society for Stem Cell    Research encourages physicians to answer their 
patients’ questions about unproven stem cell interventions abroad but advises that they actively 
discourage patients from seeking unproven stem cell interventions outside of  clinical trials owing to 
the “potential physical, psychological, and financial harm” of these interventions.14 Based on Canadian 
patients’ trust in their  family  physicians  and the role of these physicians in providing continuity  of 
care, some have argued that physicians have a responsibility to educate about the limits and potential 
harms of these interventions.11,15 These sources suggest that physicians must respect their patients’ 
decisions whether or not to go abroad for this care; however, they should also inform their patients’ 
decision making, including potentially warning patients about the dangers of unproven interventions 
if doing so is consistent with their work- load, expertise, and best judgment. 
Legal obligations 
The doctrine of informed consent requires Canadian physicians to disclose treatment information 
that a reasonable patient would want in that context.16 Generally, this means that physicians must 
answer all questions posed by patients and share with patients all material information concerning 
the nature of the proposed intervention and alternative interventions, including benefits, risks, 
and likely outcomes.17 Although the informed consent standard applies  when  physicians are 
providing treatment, we think it is reasonable to suggest similar principles should also guide 
physicians’ conduct when patients are seeking information about unproven treatments, particularly 
when patients are considering pursuing such treatments as an  alternative to  conventional  therapy 
offered  by  the  physician. In this role, physicians act much as they do when they refer their patients 
to specialists within Canada. In such cases, patients require information to enable autonomous 
decisions regarding their treatment. Moreover, in this context patients entrust their health and safety 
to their family physicians, even if these physicians are not offering treatment themselves. For this reason, 
the duty of physicians to disclose material risks of an intervention is rein- forced by the fiduciary nature 
of the physician-patient relationship, which demands physicians act in their patients’ best 
interests.18,19 Although courts have occasionally permitted physicians to withhold information when 
patients’ well-being might be seriously threatened as a result of disclosure, the scope of this privi-   
lege is highly circumscribed.17 Case law suggests that it    is better for physicians to divulge the proper 
information to patients and then ameliorate any adverse con- sequences by comforting and reasoning 
with patients instead of avoiding the  disclosure.20
Although, to our knowledge, Canadian courts have not considered whether physicians are legally 
required proactively to inform patients of unproven therapies available in another country, 
American jurisprudence offers some clues about reasonable  medical  practice in such cases. 
Physicians’ duty to inform does not typically require proactive disclosure of interventions that are 
unproven and unavailable locally. When expressly asked by patients about pursuing unproven 
interventions abroad or when it becomes clear a patient has decided to undergo such an 
intervention, family physicians are obliged to supply patients with relevant, evidence-based 
information, a standard that does not require the proactive disclosure of interventions  that lack 
regulatory approval.21,22 For example, physicians ought to discuss the health and financial risks 
associated with MT in general, as well as the unproven intervention in question, and explain  to  
patients  how the risks, benefits, and uncertainties concerning the unproven intervention compare 
with those of conventional treatment so as to allow patients to make knowledgeable treatment 
decisions. Further, physicians should point out the challenges that patients might face when follow-
up care is required in the home country. If the unproven intervention is known to cause serious harm,  
physicians’  fiduciary  responsibility  might  involve a fairly onerous duty of disclosure.21 This is not to 
say   that physicians should coerce patients or attempt to undermine their autonomy, but that 
physicians should make their concerns with the intervention clear and make sure to effectively 
communicate material information so that patients can make informed decisions. Moreover, when 
parents have made the decision on behalf of pediatric patients to pursue unproven interventions 
abroad  against  medical  advice,  doctors  might in extreme circumstances be required to report 
the situation to child welfare authorities, especially if the unproven intervention has clear risks and 
safer alter- native treatment is  available.23 
Navigating  and  clarifying obligations 
There is considerable overlap between the ethical and legal obligations of family physicians of 
patients seeking unproven interventions abroad. Canadian family physicians should provide patients 
with requested information about these interventions to the best of their ability and should respect 
patient autonomy around decisions regarding their care. Physicians also have a responsibility to 
protect the welfare of their patients and should inform them about any concerns surrounding 
unproven interventions and discuss proven alternatives when they are available. 
Several pressing questions remain  unanswered. 
• Given the lack of reliable information about unproven interventions, how active should physicians be
in informing themselves about such interventions, particularly when the interventions are not
available in  Canada? 
• How can physicians maintain a positive physician- patient relationship and respect patients’
hope for improved health while protecting patient safety? 
• Under what conditions, if any, may physicians refuse  to offer follow-up care to their patients
following treatment received abroad? 
• Should physicians be warning patients only about concerns with the effect of decisions on
the patients themselves or should they also discuss the effects on third parties, including citizens in 
host countries for these interventions and the potential for undermining well designed research trials 
on new  interventions? 
We call for Canadian medical educators to challenge family physicians in training with questions 
such as these, encouraging them to grapple with the implications of MT for their clinical practice from 
the  outset. 
At present, Canadian family physicians face too much uncertainty in light of the growing trend of 
Canadians seeking unproven interventions via MT. They  should  face this challenge by informing 
themselves about relevant trends in travel abroad for unproven interventions,  seeking to better 
understand the issues their patients are struggling with in this area, and give careful consideration  to 
their ethical and legal obligations toward these patients. At the same time, physicians deserve clearer 
ethical and  legal guidelines from professional colleges and associations around their roles in these 
cases so that they can execute their obligations without fear and confusion. The Canadian medical 
leadership is herein called upon to engage with legal, ethics, and policy scholars to actively work toward 
developing this guidance. 
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